鼻咽癌放疗后18F-氟脱氧葡萄糖正电子发射断层显像反应的临床意义
回顾143例鼻咽癌患者放疗完成后6个月内行18F-FDG PET,按原发灶和区域淋巴结分别判读为阴性或阳性,参考标准为组织病理学或临床/影像随访。原发灶和淋巴结PET阴性的阴性预测值分别为100%和99%;淋巴结PET阳性且SUVmax>2.5者5年总生存和无远处转移生存显著劣于淋巴结PET阴性或阳性但SUVmax≤2.5者。
要点
- 放疗后6个月内18F-FDG PET对原发灶和淋巴结残留病灶的阴性预测值分别达100%和99%。
- 淋巴结PET阳性且SUVmax>2.5者5年总生存44% vs 86%(p=0.004),无远处转移生存36% vs 85%(p<0.001)。
- 原发灶PET灵敏度100%、特异度84%、阳性预测值8%;淋巴结PET灵敏度67%、特异度80%、阳性预测值7%。
核心结论
- 鼻咽癌接受根治性(放化疗)后6个月内行18F-FDG PET对预测残留病灶有高阴性预测值,并对长期治疗结局有预后价值。
研究设计与样本
- 回顾性分析2001年至2012年间143例鼻咽癌患者,均在放疗完成后6个月内行18F-FDG PET;原发灶(T-)和区域淋巴结(N-)分别判读为PET阴性或阳性,参考标准为组织病理学确认或临床/影像随访。
关键影像表现/征象
- 原发灶PET阴性者占83%,淋巴结PET阴性者占66%。
- PET阳性定义为残留局灶性18F-FDG摄取增高,程度高于周围肌肉或血管。
- 淋巴结PET阳性且SUVmax>2.5者5年总生存率44% vs 淋巴结PET阴性或阳性但SUVmax≤2.5者86%(p=0.004)。
- 淋巴结PET阳性且SUVmax>2.5者5年无远处转移生存率36% vs 淋巴结PET阴性或阳性但SUVmax≤2.5者85%(p<0.001)。
诊断标准与关键数值
- 原发灶PET:灵敏度100%、特异度84%、阳性预测值8%、阴性预测值100%。
- 淋巴结PET:灵敏度67%、特异度80%、阳性预测值7%、阴性预测值99%。
- PET阳性判读标准:残留局灶性18F-FDG摄取高于周围肌肉或血管。
- 淋巴结PET阳性且SUVmax>2.5提示5年总生存和无远处转移生存显著劣于淋巴结PET阴性或阳性但SUVmax≤2.5者。
临床应用与阅片要点
- 放疗后6个月内18F-FDG PET对排除原发灶和淋巴结残留病灶有高阴性预测值。
- 淋巴结PET阳性且SUVmax>2.5的患者可能从更积极的治疗中获益(作者认为)。
- 作者指出需进一步研究验证放疗后18F-FDG PET的临床意义。
局限性
- 作者指出需进一步研究验证放疗后18F-FDG PET的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of the present study was to evaluate the clinical significance of the post-radiotherapy 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) response for detecting residual disease and predicting survival outcome in patients with nasopharyngeal cancer.
METHODS: We reviewed 143 patients with nasopharyngeal cancer who underwent 18F-FDG PET within 6 months after completion of radiotherapy between 2001 and 2012. 18F-FDG PET findings at the primary tumor (T-) and regional lymph nodes (N-) were separately assessed and considered negative [PET (-)] or positive [PET (+)] depending on the remaining focal increased uptake of 18F-FDG that was greater than that of the surrounding muscle or blood vessels. The standard of reference was histopathological confirmation or clinical/imaging follow-up. Overall survival (OS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRRFS) rates were estimated from the date of the start of radiotherapy.
RESULTS: The median follow-up period was 73 months (range, 9-182 months). Overall, 83 and 66% of patients achieved T-PET (-) and N-PET (-) responses, and the negative-predictive values (NPVs) for T- and N- were 100 and 99%, respectively. The sensitivity, specificity, and positive-predictive value were 100, 84, and 8% for T-, and 67, 80, and 7% for N-, respectively. The 5-year OS, DMFS, and LRRFS rates were 83, 83, and 87%, respectively, and patients with N-PET (+) with SUVmax >2.5 showed significantly inferior 5-year OS and DMFS rates than patients with N-PET (-) or N-PET (+) with SUVmax ≤2.5 (44 vs 86%, p = 0.004; 36 vs 85%, p < 0.001).
CONCLUSION: In patients that have received definitive (chemo)radiotherapy for nasopharyngeal cancer, 18F-FDG PET within 6 months of completion of treatment has a high NPV for predicting residual disease and is prognostic for long-term treatment outcomes. Patients with remaining focal increased uptake of 18F-FDG at lymph nodes may benefit from more aggressive treatments, and further studies are needed to validate the clinical significance of post-radiotherapy 18F-FDG PET.
ADVANCES IN KNOWLEDGE: We found that post-radiotherapy 18F-FDG PET findings have a high NPV for detecting residual disease and are a significant prognostic factor for treatment outcomes.
引用
- Jeong Y, Jung IH, Kim JS, et al. Clinical significance of the post-radiotherapy 18F-fludeoxyglucose positron emission tomography response in nasopharyngeal carcinoma. Br J Radiol. 2019. PMID: 30102562. doi:10.1259/bjr.20180045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。